Psilera Bioscience
Private Company
Total funding raised: $2.3M
Overview
Psilera Bioscience is a private, preclinical-stage biotech pioneering a new class of serotonergic compounds termed neuroplastogens for neurological and psychiatric conditions. Leveraging a proprietary library of over one million novel compounds and a leadership team with deep industry experience, the company is building a pipeline of non-hallucinogenic and short-duration psychedelic-inspired therapeutics. Its strategy focuses on creating first-in-class drugs with improved safety and accessibility profiles compared to classical psychedelics, targeting significant unmet needs in mental health.
Technology Platform
Proprietary drug discovery platform for designing next-generation neuroplastogens; includes a library of over 1 million novel serotonergic compounds across six families, aimed at creating non-hallucinogenic or short-duration therapies that promote neural plasticity.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Psilera competes in the rapidly evolving psychedelic-inspired medicine sector, facing competition from both public companies advancing classical psychedelics (e.g., COMPASS Pathways, MindMed) and other biotechs developing next-generation compounds (e.g., Gilgamesh Pharmaceuticals, Atai Life Sciences' portfolio). Its differentiation lies in its extensive proprietary compound library and specific focus on creating practical, at-home therapy options.